Cue Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $0.42M misses by $0.85M
Source: SeekingAlpha
2025-05-12 17:27:38 ET
More on Cue Biopharma
- Cue in pact with Boehringer for autoimmune and inflammatory diseases
- Cue Biopharma stock falls after pricing capital raise of $20M via securities offering
- Seeking Alpha’s Quant Rating on Cue Biopharma
- Historical earnings data for Cue Biopharma
Read the full article on Seeking Alpha
For further details see:
Cue Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $0.42M misses by $0.85M
Cue Biopharma Inc.
NASDAQ: CUE
CUE Trading
-3.24% G/L:
$0.3139 Last:
1,339,487 Volume:
$0.309 Open:
CUE Latest News
March 09, 2026 08:00:00 am
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
February 17, 2026 08:00:00 am
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
February 12, 2026 08:00:00 am
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
CUE Stock Data
$30,117,989
80,549,371
0.16%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
